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Abstract
Background Data collected for medical, filing and
administrative purposes in electronic patient records
(EPRs) represent a rich source of individualised clinical
data, which has great potential for improved detection of
patients experiencing adverse drug reactions (ADRs),
across all approved drugs and across all indication areas.
Objectives The aim of this study was to take advantage of
techniques for temporal data mining of EPRs in order to
detect ADRs in a patient- and dose-specific manner.
Methods We used a psychiatric hospital’s EPR system
to investigate undesired drug effects. Within one work-
flow the method identified patient-specific adverse events
(AEs) and links these to specific drugs and dosages in a
temporal manner, based on integration of text mining
results and structured data. The structured data contained
precise information on drug identity, dosage and
strength.
Results When applying the method to the 3,394
patients in the cohort, we identified AEs linked with a
drug in 2,402 patients (70.8 %). Of the 43,528 patient-
specific drug substances prescribed, 14,736 (33.9 %)
were linked with AEs. From these links we identified
multiple ADRs (p \ 0.05) and found them to occur at
similar frequencies, as stated by the manufacturer and in
the literature. We showed that drugs displaying similar
ADR profiles share targets, and we compared submitted
spontaneous AE reports with our findings. For nine of
the ten most prescribed antipsychotics in the patient
population, larger doses were prescribed to sedated
patients than non-sedated patients; five patients exhibited
a significant difference (p \ 0.05). Finally, we present
Key Points
Temporal data mining of patient-specific notes
stored in electronic patient record (EPR) systems can
be used for pharmacovigilance in a clinical, multi-
diseased and polypharmacy population.
Structured and unstructured data accumulated in the
EPRs permits dose-specific monitoring of adverse
drug reactions (ADRs) and observations of patients
affected by ADRs in the actual clinical setting.
High throughput analysis of the data already
collected in EPRs by healthcare providers can be
used to verify suspected correlations, as well as
suggest novel likely correlations between drugs and
adverse events.
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two cases (p \ 0.05) identified by the workflow. The
method identified the potentially fatal AE QT prolonga-
tion caused by methadone, and a non-described likely
ADR between levomepromazine and nightmares found
among the hundreds of identified novel links between
drugs and AEs (p \ 0.05).
Conclusions The developed method can be used to
extract dose-dependent ADR information from already
collected EPR data. Large-scale AE extraction from
EPRs may complement or even replace current drug
safety monitoring methods in the future, reducing or
eliminating manual reporting and enabling much faster
ADR detection.
1 Introduction
Despite increasing knowledge and prevention methods,
adverse drug reactions (ADRs) continue to impact a large
part of the patient population [1, 2], leading to hospitali-
sations and substantial healthcare expenses [3, 4]. Several
of these noxious and unintended responses, occurring at
normal doses [5], have been identified after approved drugs
were introduced on the market, in some cases resulting in
serious harm and ultimately in drugs being withdrawn [6].
This highlights that drug safety cannot be fully assessed
solely through the preclinical [7] and clinical stages [8].
Clinical trials only expose a limited number of subjects in
selected groups, are often underpowered to identify all
ADRs, and the limited time window often prevents iden-
tification of ADRs with late onset [8]. Thus post-approval
surveillance is an essential part of every drug’s lifecycle.
Additionally, observational data, where co-morbidities and
concomitant drug use are present, has been suggested to
represent a better measurement of harms experienced by
actual patients in comparison to data collected from clini-
cal trials [9].
For the past 40 years, medical product agencies have
relied heavily on spontaneous reporting systems for post-
approval drug safety surveillance [10–12]. Adverse events
(AEs) occurring during treatment are collected and ana-
lysed in databases such as the US FDA Adverse Event
Reporting System (FAERS) and the WHO VigiBase [13].
The aim of these analyses is to generate hypotheses of
causal relationships between drugs and AEs, referred to as
signal detection [14]. However, there are several recogni-
sed shortcomings with this scheme. The main issues are the
widespread underreporting and reporting bias largely
caused by submitters prioritising other tasks, selectively
reporting severe less-known AEs, and data quality issues
such as report duplication [8, 11, 15]. This is despite efforts
to improve reporting in several countries through tightened
legislation making suspected AE reporting mandatory [10].
Alternatively, AE relationships can be tracked in health
registries. The FDA Sentinel Initiative [12], the EU-ADR
project [16] and the Observational Medical Outcomes
Partnership [17] aim at large-scale aggregation and inte-
gration of data captured in databases. However, far from all
AE evidence is reported or captured in coded formats. It is
thus desirable to monitor AEs from the detailed clinical
observations already recorded by healthcare providers in
electronic patient records (EPRs), in particular the clinical
narratives. This is in contrast to the data stored in an
electronic health record (EHR), which consist of computer-
readable data represented according to relevant controlled
vocabularies [18].
In this study we use temporal data mining of an EPR
system to link AEs to drugs, in a multi-diseased and poly-
pharmacy population.
2 Methods
2.1 Study Population
We gained full access to the EPR system of a tertiary
Danish psychiatric hospital with free text and structured
data from 3,394 patients prescribed at least one drug
between 1998 and 2010. The patient population (electronic
supplementary material [ESM] 1) ranged from 17 to
86 years of age, mean age was 43.6 years (standard devi-
ation 12.5 years) at the midpoint of treatment, counting all
admissions for each patient as one single period. The
male:female ratio was 2:1. The average total clinical nar-
rative was 66,000 words and 1,400 notes per patient; this
high number is related to the nature of this patient popu-
lation. Communication plays an even more vital role in
diagnosis and treatment planning within psychiatry com-
pared with other medical specialties.
2.2 Temporal Data Mining
The overall strategy of our approach is to combine struc-
tured prescription data with AEs extracted from clinical
notes to identify AEs occurring between drug introduction
and discontinuation (Fig. 1). The approach is enabled by
the time-stamped arrangement of both the structured and
unstructured data. All AEs were passed through filters to
discard AEs within text passages with words suggesting
that the mentioned AE did not happen, affected someone
else or happened in the past [19]. To eliminate pre-existing
conditions, we filtered out all AEs present prior to drug
introduction or coincided with indications of the drug. Only
AEs retained after filtering were used for the subsequent
analyses.
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2.3 Drug Prescriptions
The structured prescription-data contains all orders made in
the hospital, meaning that all prescriptions are stored in the
electronic records. We extracted the drug identity, the total
daily dose, as well as the times of introduction and dis-
continuation for each prescription, including premature
discontinuation of a prescribed drug not necessarily being
the same as the last treatment day on the original pre-
scription. The total daily dose was calculated for each
treatment day, including all prescriptions and allowing
changes in dosing to be accounted for. Depot formulations
were considered continuously over the whole dosing
period.
2.4 Adverse Event (AE) and Drug Name Identification
It has previously been shown that investigation of clinical
narratives can give an up to fourfold boost in the number of
unique diagnoses associated with each patient [20], when
comparing to assigned International Classification of Dis-
eases (ICD) 10 codes. Considering that only a subset of the
data is available in coded formats and that many code
formats are not designed for AE investigation, it is desir-
able to detect AE in clinical narratives.
We have previously developed a method for identifica-
tion of possible AEs in unstructured clinical narrative text
[19]. The method is based on a named entity recognition
(NER) tagger, which identifies matches in the clinical text
to a dictionary of drug-related AEs. It takes into account
alternative spelling, synonyms and inflectional variants,
which are merged and treated as the same AE. Moreover,
anatomical structures are linked, so that cell types and
tissues are merged to larger anatomical structures, e.g.
hepatocellular damage and liver damage. Together these
features allow for appropriate grouping of effects. The
current version has been improved to handle more than
4 9 1012 different ways of writing descriptions of drug
related AEs. A negation and other negatives filtering step
removes disqualified concepts. This includes negations or
mentions of other subjects. Furthermore, information about
undesirable effects given from the prescriber or AE
descriptions from the past that are disqualified for temporal
reasons as these occurred at some other time point were
filtered in a similar manner.
Understanding the complexity of AE descriptions
requires interpretation of clinical narratives. We therefore
merged terms that are not necessarily synonyms but have the
same medical implication, e.g. kidney failure and elevated
creatinine (ESM 2). We also extended the method with trade
Fig. 1 AE extraction and data integration. AEs were extracted between drug introduction and discontinuation, where we filtered out AEs if the
text in the clinical note suggests it did not happen, affected someone else or happened in the past. Additionally, we filtered all indications of the
drug and ADRs related to additional drugs. Finally, all pre-existing conditions were removed. Remaining AEs were sorted into ADRs and
possible ADRs; the latter was presented for manual review. ADR adverse drug reaction, AE adverse event, EPR electronic patient record, SPC
Summary of Product Characteristics
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names and generic names of all drugs authorised in Den-
mark, including likely spelling variants and misspellings
based on the interchangeable characters, phonetic similarity,
and endings. For all subsequent analyses we considered
drugs with the same active substance as a single drug. We
used the Anatomical Therapeutic Chemical (ATC) classifi-
cation system [21] to group drugs into classes. To assess how
well this method performed, we manually curated 200 ran-
domly selected clinical notes, according to a previously
described method [19]. On this set, the method identified
possible AE words and drugs with a 75 % recall (sensitivity)
and 95 % precision (positive predictive value).
2.5 AE Filtering
When an AE is mentioned in the clinical narrative it does
not necessarily imply that the patient experienced the AE.
Prescribers are required to document that they have
informed patients about the ADRs they may experience.
Also, AEs and indications overlap, meaning that the
mentioned AE may be the very reason why the patient
received the drug.
We used a set of filters to address these and other
complications (Fig. 1). First, we considered only AEs if
they were mentioned at least 1 day after drug introduction.
The only exception was anaphylaxis, which we recorded on
the introduction day. The first day was excluded in order to
reduce errors in AE detection originating from the pre-
scribers’ information about the treatment risks. Second, we
used linguistic filters described elsewhere [19] to disqualify
AEs in text passages with negations, words suggesting that
the mentioned AE did not happen, affected other subjects,
described previously experienced events or information
about ADRs. In this way we were able to filter out AEs
recorded on a particular date, taking into account previ-
ously experienced AEs or AEs that might occur in the
future. We similarly disregarded AEs from sentences that
mentioned two or more drugs as this implied information
was given to the patient from a healthcare provider or
implied a medical history about the patient. Third, we fil-
tered out indications listed in the official product docu-
mentation required within the EU, namely the Summary of
Product Characteristics (SPCs) [22, 23]. We used the SPCs
as of 4 November 2011, combined indications for all drugs
containing the same active substance to eliminate manu-
facturer-specific differences, and manually added certain
off-label uses. Additionally, the filtering was extended to
disqualify contraindications and secondary effects of the
indication to the drug in question. Fourth, we filtered AEs
on the first treatment day of any additional drug introduced
coinciding with its ADRs. Finally, we also filtered out pre-
existing conditions that were not indications of the drug,
but were mentioned within the last 14 days before the drug
was prescribed. Different time intervals between 1 to
4 weeks were analysed.
2.6 Statistical Analyses, Frequencies and Adverse
Drug Reaction (ADR) Characteristics
Next, we used a statistical approach to identify possible
causal links between drugs and AEs, building upon
counting the extracted and merged AEs once per patient
and drug.
Two confidence levels were used for drug–AE pairs.
The lower level included all AEs identified throughout the
entire treatment period. The higher level further requires
within-sentence co-occurrence of the AE and the same
drug as is in the prescription, and was used in all calcu-
lations except for dose–ADR relationship.
All AEs were assigned to a 2 9 2 contingency table
[14], consisting of patients on drug X or not, and patients
experiencing AE Y or not. We tested each drug–AE pair
for statistically significant overrepresentation using one-
sided Fisher’s exact test, and used the Benjamini–Hoch-
berg procedure to control the false discovery rate (FDR)
using a threshold of 5 %. Furthermore, the odds ratio (OR)
and the proportional reporting ratio (PRR) were calculated.
Additionally, a value corrected by matching for gender and
age was calculated for all drug–AE pairs. Each of the
statistically significant drug–AE pairs was compared with
the ADRs listed in the ‘undesirable effects’ section of the
SPC of the drug. In case of multiple drugs with the same
active substances, we included the ADRs from all the
SPCs, thereby eliminating product differences. AEs not
identified as known ADRs, and therefore not known for the
drug in question, were classified as possible ADRs for
further manual review (Fig. 1). Here, comorbidities, con-
comitant drugs and other factors such as biological plau-
sibility can be assessed.
Absolute frequencies, defined as the proportion of
patients treated with a certain drug who are affected by a
specific AE, were calculated from structured drug-pre-
scription data and AEs identified in the clinical narratives.
We also calculated the relative frequencies, defined as the
proportion that a specific AE makes up of all reported AEs
for a drug.
From the statistically significantly overrepresented
ADRs, we calculated the ADR profile similarity for any
two drugs using the Jaccard similarity coefficient. This
resulted in a drug network based on ADR profile similarity
identified in our study population.
To investigate dose–ADR relationships, we included
events in the first continuous steady dosage interval,
between introduction and discontinuation, in patients pre-
scribed the drug for at least 5 and 10 days (also including
patients in the 5-day observation period). Only standing
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oral orders were considered and patients on depot formu-
lations were excluded. The dose distributions prescribed
non-sedated and sedated patients for each interval were
analysed for statistically significant differences using the
two-sided t-test.
3 Results
By integrating text mining results and structured data in a
temporal manner, we were able to identify AEs docu-
mented in the hospital’s EPR system and link these AEs
with the drugs used.
3.1 Drug Fingerprint and AEs Linked to Drugs
The distribution and prescription patterns were examined
and revealed a median usage of 14.5 drug substances over
the study period (Fig. 2a). Only ten drugs were prescribed
to more than 1,000 patients. To give an overview, we
summarise the drug prescriptions as a network that cap-
tures how often drugs from a given class are prescribed and
how often drugs from two different classes are prescribed
to the same patient (Fig. 2b).
Of the 3,394 patients prescribed at least one drug, our
method found AEs in 2,402 patients (70.8 %). In total, of
the 43,528 patient-specific drug substances prescribed in
the study we identified 14,736 (33.9 %) AEs linked to a
drug. Of these, 47 % were linked to antipsychotics (N05A),
13 % to drugs used in addictive disorders (N07B), and 9 %
to antiepileptics (N03A). The classes with the highest
average AEs per prescription were psychostimulants,
agents used for ADHD and nootropics (N06B) [1.13
AEs/prescription], antipsychotics (N05A) [0.88 AEs/pre-
scription] and drugs used in addictive disorders (N07B)
[0.76 AEs/prescription]. In total 2,104 statistically signifi-
cantly overrepresented drug–AE pairs were extracted, and
1,252 corrected drug–AE pairs were significant.
We further analysed the data for sensitive patients. Of
the patients where we found an AE, 26 (1.1 %) patients
experienced the same AE for three or more drugs. In the
analysis we found 48 (2.0 %) patients were associated with
more than ten AEs to a single drug.
3.2 Extracted ADR Frequencies
Based on the extracted ADRs from the clinical texts and
the structured prescription data, we calculated the fre-
quency with which a specific ADR occurred. We compared
the absolute frequencies of the 150 most statistically
overrepresented extracted ADRs prescribed to more than
ten patients with the manufacturer-stated frequencies
(Fig. 3). Only 11 were omitted as they had frequencies
\1/1,000 according to the SPC, but in our data prescribed
to 328 patients or less. Compared with the SPCs, we esti-
mate common ADRs to occur at similar frequencies, very
common ADRs slightly lower, and uncommon ADRs
slightly higher.
We further compared the findings of our method with
suspected AEs that had been reported to the Danish Med-
icines Agency (now the Danish Health and Medicines
Authority) [ESM 3], showing we can extract more AEs
statistically significantly associated with a particular drug
in a single hospital than reports in the database for the same
drug.
In addition to the comparison between AE–drug pairs
identified by our method and ADRs stated in the SPCs used
to identify known correlations, we also compared our
results with unlikely associations [24]. This second com-
parison showed that none of the ‘negative control’ asso-
ciations were identified by our method.
3.3 ADR Profiles
Placing the drugs in a network based on their actual
ADR profiles demonstrated that drugs with similar indi-
cations tend to group together, and have similar ADR
profiles (Fig. 4), which was expected because in many
cases they also have common targets [25]. For example,
this is the case for psycholeptics (N05A) and psychoan-
aleptics (N06A). Drugs with similar active substances but
different indications also group together (e.g. opioids).
Finally, there are examples of drugs that have similar
ADR profiles despite neither having similar indication
nor being chemically similar, e.g. laxatives (A06A) and
antibacterials for systemic use (J01). The contrast being
antiepileptics (N03) displaying diverse profiles, not
unexpected since antiepileptics are known to vary in
terms of ADRs [26].
3.4 Dose–ADR Relationship
To test if events where patients experiencing a certain ADR
were related to drug dosage, we focused on the most fre-
quently identified AE, namely sedation, which was asso-
ciated with 940 patients. As many antipsychotics cause
sedation [27–29], we selected the ten most prescribed an-
tipsychotics in the cohort for investigating dose–ADR
relationships. For the first steady dosage exceeding 5 and
10 days, the dose distribution of non-sedated and sedated
patients were compared (Table 1). For all drugs except
haloperidol, the groups that experienced sedation had a
higher mean dose compared with the groups that did not.
The 5-day period displayed a statistically significant dif-
ference in four drugs, which rose to five drugs in the 10-day
period.
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(a)
(b)
Fig. 2 Patient population. a Distribution of unique recorded drug substance prescriptions per patient and average proportions of first-level ATC
group prescription. The total number of drug substances prescribed to a patient throughout the study (x-axis) and the proportions of drug classes
prescribed to the patients prescribed this number of drug substances (y-axis). Anesthetics (N01) and analgesics (N02) are separated from nervous
system (N), permitting illustration of psychiatric drug prescription. b Within-patient drug prescription between second-level ATC groups. Nodes
represent the second-level ATC, sizes, the amount prescribed and colour of the anatomical main group. Edges show within-patient drug
prescription between second-level ATC groups, while darker edges indicate more frequent co-administration or within-patient prescription. ATC
Anatomical Therapeutic Chemical
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3.5 Cases of Severe and Likely ADRs
The vast majority of the ADRs we identified and quantified
were of a less severe nature, but we also associated drugs
with potentially fatal AEs. We identified three patient cases
(0.8 %) of methadone-associated QT interval prolongation
[30, 31] of the 392 patients in methadone treatment
(p = 0.008; FDR = 0.02), verified by manual chart
review.
The most significant, not documented correlation
(p \ 0.001; FDR \ 0.001) was between levomepromazine
and nightmares, which is not listed as an ADR in the SPC
but still represents a plausible and probable effect of anti-
psychotics [32]. We found nightmares occurring in 4 of
523 patients (0.8 %), verified by manual chart review. In
this analysis, we excluded any nightmares occurring during
concurrent treatment with any known nightmare-inducing
drug. These drugs were extracted from the Danish SPCs.
The existence of such correlation was previously suspected
by some of the hospital’s clinical psychiatry staff. Baseline
patient characteristics are retained from the cohort, which
is essentially heavily treated with psychiatric drugs.
4 Discussion
Through this analysis we were able to identify thousands of
described ADRs, to suggest non-described likely ADR
correlations, and to recapitulate many of the known char-
acteristics of drugs and ADRs in a patient-specific manner.
The described method demonstrates an individualised
model for drug safety monitoring based on the rich data
already collected by healthcare providers. In contrast to
earlier work [33], for the first time we identified ADRs in a
dose-specific manner by integrating prescribed exposure
from structured data and unstructured clinical narrative
text. A key feature that makes this possible is that we
merge terms that have the same anatomical location or
medical implication, even if they are not merely alternative
spelling variants. We demonstrate the potential on a psy-
chiatric cohort, a population with higher frequency of
ADRs than other specialties [34], but our method is not
specific for this domain and therefore also extends into
other medical specialties. In addition, neither is the
approach language-specific as the ADR dictionaries may
be replaced with dictionaries based on other languages.
The links between drugs and AEs are uncovered in a
high-throughput manner from raw clinical information that
requires essentially no extra work for professionals in the
healthcare system and could eventually reduce the burden
of submitting spontaneous reports. Additionally, time and
phenotypic data loss is minimised as no information has to
be rewritten, transferred, transformed or coded into a sep-
arate database [13, 16, 35]. The linking is done by inves-
tigating actual clinical data, which differ many times from
the artificial conditions of a clinical trial, where co-mor-
bidities and concomitant drug treatments are normally
excluded.
Due to the limited number of subjects in the cohort and
the large number of different drugs prescribed, the number
of individuals prescribed each drug only sometimes
reaches the number of participants in a phase III clinical
trial [13]. Despite this, we were able to identify thousands
of statistically significant links between drugs and AEs, and
in many cases even estimate their frequencies close to
those listed in the SPCs. We extracted lower frequencies of
very common ADRs, possibly explained by these being so
common the clinician never records them. On the other
hand, we estimate slightly higher frequencies for the most
significant rare (C1/10,000 to \1/1,000) and very rare
(\1/10,000) ADRs. We cannot conclude if the frequencies
listed in the SPC should be higher because too few patients
were prescribed these drugs to compare them with the
frequencies listed in the SPCs. Furthermore, the observed
difference is possibly explained by the fact that the study
population includes chronic and hospitalised patients,
sometimes with extreme polypharmacy and doses. With
Fig. 3 ADR frequency comparison. Absolute frequency comparison
between the most statistically significant extracted ADRs at least
prescribed to ten patients and the manufacturer listed. ADR adverse
drug reaction, EPR electronic patient record
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that said, our method might show the clinical reality better
and therefore the frequencies differ from the carefully
selected patients included in a clinical trial and presented in
the SPCs.
Our method could also be used for discovering very rare
ADRs, which are notoriously hard to identify in smaller
studies such as most randomised clinical trials [36]. In this
relation, nationwide EPR systems could be of interest,
indisputably providing a larger study population, but still
permit individual drug response observations. Moreover,
the method has no constraints preventing integration into
efforts such as the FDA Sentinel Initiative [12] where
sensitive data is not transferred outside the originating
organisation.
The dose difference between groups unaffected and
affected by a particular ADR could possibly point at dose
limits that should not be exceeded if it is desirable to
prevent a certain ADR, thereby individualising the treat-
ment for each patient. Haloperidol, which has been asso-
ciated with less sedative effects [27], is the only drug
where the non-sedated proportion is given a larger mean
dose. This is possibly explained by the prominent extra-
pyramidal symptoms associated with an increase in halo-
peridol dose, resulting in a reduction in attention to
sedation compared with the other notable effects, as these
increased with dose increments. Comparing our results
with the tolerability of antipsychotics, similar patterns are
revealed [37]. Substances displaying a higher proportion of
sedated patients, such as ziprasidone, also display more
sedation compared with placebo; similarly haloperidol and
aripiprazole show a lower proportion of sedated patients in
our study, as well as less sedation compared with placebo
in the study by Leucht et al. [37] The sedative profile of
chlorprothixene seen in the investigation might be the real
Fig. 4 ADR-profile network. Condensed force-directed ADR-profile network, represented by the 500 largest Jaccard similarity coefficient
values. Nodes depict drug substances, identified by the fifth-level ATC code, sizes indicate the number of ADRs detected. Subgroups of the ATC
group Nervous system (N), are given separate colours, except for grey, which symbolises all other drug substances. Edges display ADR profile
similarity, while darker edge indicates higher similarity. ADR adverse drug reaction, ATC Anatomical Therapeutic Chemical classification
system
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indication for many prescriptions of this drug. The decision
to prescribe chlorprothixene very likely involves its seda-
tive effects, despite it not being stated in the prescription
decision. This is showing another quality of the method.
It is most likely that further fine-tuning of the extraction
of information would present further possibilities of cor-
recting for additional confounding factors to a future ana-
lysis. This also applies to the construction and usage of
EPR systems, which are constantly becoming more
advanced, interconnected and information-rich.
Any drug–AE pair the method identifies as statistically
overrepresented and which is not previously known to be
associated, is presented for manual review. This output
occasionally contains trivial correlations and we recognise
the value of further improvements limiting the output,
potentially by a similar method, as suggested by Tatonetti
et al. [38]. Alternatively, the output could also simply be
analysed in a similar way as spontaneous reports, generating
signals validated in a separate investigation [5, 10, 13].
One aspect we are not investigating is patient self-
administered drugs and drugs used prior to admission, as
we do not have information on this. These drugs can
potentially cause effects that we interpret as AEs and link
to another drug, although they are unlikely to give rise to
statistically significantly overrepresented ADRs. Another
limitation is the non-perfect extraction from the narratives,
where more advanced linguistic techniques would likely
improve the performance of the method. There is also a
risk of AEs never being recorded in the first place, but this
type of error would most likely affect less severe AEs. Due
Table 1 Non-sedated and sedated patients taking antipsychotic drugs
Drug\stable dose period 5 days 10 days
No sedation Sedation p-value No sedation Sedation p-value
Chlorprothixene
Mean dose 92.56 122.67 0.005 94.14 121.14 0.003
n (%) 621 (82) 133 (18) 485 (70) 211 (30)
Olanzapine
Mean dose 14.32 18.33 0.01 14.07 17.28 0.005
n (%) 569 (83) 117 (17) 466 (71) 191 (29)
Clozapine
Mean dose 263.63 354.49 0.04 268.79 377.05 0.003
n (%) 188 (83) 39 (17) 163 (73) 61 (27)
Quetiapine
Mean dose 255.55 325.11 0.03 272.14 332.84 0.02
n (%) 545 (81) 127 (19) 480 (73) 177 (27)
Risperidone
Mean dose 2.68 2.97 0.22 2.80 2.96 0.38
n (%) 329 (82) 74 (18) 275 (72) 106 (28)
Levomepromazine
Mean dose 69.87 98.31 0.14 69.87 88.44 0.25
n (%) 139 (80) 34 (20) 114 (70) 48 (30)
Zuclopenthixol
Mean dose 10.58 13.83 0.16 11.60 12.00 0.82
n (%) 212 (88) 29 (12) 173 (77) 51 (23)
Haloperidol
Mean dose 7.90 4.04 0.007 7.81 6.08 0.31
n (%) 89 (88) 12 (12) 70 (80) 18 (20)
Aripiprazole
Mean dose 12.84 13.95 0.54 13.59 15.02 0.30
n (%) 219 (86) 37 (14) 192 (77) 56 (23)
Ziprasidone
Mean dose 94.17 118.82 0.09 101.28 125.00 0.04
n (%) 127 (79) 34 (21) 109 (73) 40 (27)
Distribution of non-sedated and sedated patients during the first stable dosage interval of 5 and 10 days after drug introduction. The ten most
prescribed antipsychotics in descending number of total prescriptions in the study population
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to the filtering of identified possible AEs, we are not able to
find AEs identical to the indication and are thus not able to
identify deterioration in the original treatment cause. We
are currently filtering sentences containing two or more
drugs, which limits the risk of falsely linking an AE to a
drug. It also reduces the possibility of detecting drug–drug
interactions, which in any case is not our aim with this
study. Furthermore, we do not investigate late effects
appearing after drug discontinuation.
5 Conclusions
Not only do we present a high-throughput method to
identify AE correlations in noisy real clinical data, but we
also display the clinical research potential of the under-
exploited asset EPRs represent. For the first time, temporal
data mining of an EPR system is used to identify ADRs and
enable drug safety monitoring in a dose-specific manner by
integrating structured exposure data and unstructured
clinical narrative text. Our method utilises an individua-
lised model to harness highly detailed phenotypic data
already collected by healthcare providers. This type of
method may limit the critical time before a serious ADR is
identified after market introduction, thereby preventing
morbidity and mortality in the population. The described
method, in combination with future advances of clinical
tools, could provide the prescriber with real-time decision
support, highlighting possible AEs a patient is having or
has experienced.
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